Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05172310 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 29, 2021 (before its estimated June 30, 2024 completion). Its status may not reflect the trial's current state.

Record History

  1. Minor Study First Submitted
1,739 trials monitored
See 106 trials at risk
1,336 trials monitored
See 90 trials at risk
1,278 trials monitored
See 63 trials at risk
and 1 more disease
Cancers of the pancreas, bile ducts, stomach and ovaries are dismal diseases with most patients being diagnosed in advanced stages leading to a bad prognosis. These cancers can be difficult to diagnose and sometimes impossible to differentiate from underlying benign conditions. Establishing the correct diagnosis of primary cancer lesions and possible spread to other organs in time is pivotal for choosing the right therapy. Routinely applied staging procedures are however not always reliable. The main aim in this study is to evaluate the diagnostic accuracy of PET/CT with a novel radiotracer, FAPI, in the primary diagnosis of cancers in the pancreas, stomach and bile ducts as well as in patients with primary and recurrent epithelial ovarian cancer (EOC).
Trial Details
NCT Number NCT05172310
Lead Sponsor Karolinska University Hospital
Conditions
(from sponsor)
Pancreatic Neoplasms, Stomach Neoplasms, Bile Duct Neoplasms, Epithelial Ovarian Cancer
Related terms Bile Duct Neoplasms, Carcinoma, Ovarian Epithelial, Pancreatic Neoplasms, Stomach Neoplasms
Enrollment 410 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov